Dr. Lior Shaltiel reports

NUREXONE EXPANDS U.S. ENGAGEMENT ACROSS FOUR MAJOR BOSTON LIFE SCIENCES EVENTS AND PROVIDES CORPORATE UPDATE

Nurexone Biologic Inc. has made a series of United States engagements across four major life sciences events taking place in Boston from Sept. 22 to Sept. 25, 2026. The conferences will feature participants from across the global life sciences sector, including investors, scientists and representatives from leading pharmaceutical companies.

As part of the company's business development and stakeholder-engagement activities in the U.S., chief executive officer Dr. Lior Shaltiel will actively participate as speaker in three conference programs and attend the invitation-only World Medical Innovation Forum. R&D (research and development) director Dr. Tali Kizhner will also represent the company as a speaker at the 8th Exosome-Based Therapeutics Development Summit.

The conferences are expected to provide opportunities for Nurexone to present its development programs and engage with participants from across the biotechnology ecosystem, including investors, researchers, manufacturers and health care industry participants.

Separately, Dr. Lior Shaltiel, chief executive officer of Nurexone, will be available for one-on-one investor meetings in New York, N.Y., from Sept. 28 through Sept. 30; investors interested in schedulling a meeting may contact Nurexone@russopartnersllc.com.

"Boston brings together many of the people and organizations shaping the future of exosome therapeutics, including scientists, industry leaders and investors," said Dr. Shaltiel. "Our recently announced U.S. manufacturing memorandum of understanding with Made Scientific reflects our objective of establishing a commercial platform in the United States. Our participation in these events will provide an opportunity to present our development programs and engage with industry participants."

One Week, One City, Four Events

8th Exosome-Based Therapeutics Development Summit -- Sept. 22 to Sept. 24, 2026

Dr. Shaltiel and Dr. Kizhner are both confirmed speakers at the specialist conference dedicated to advancing exosome and extracellular-vesicle therapeutics. Dr. Shaltiel will participate as a panellist on Wednesday morning in the panel "Building investor confidence in the exosome space." Additionally, on Thursday, Sept. 24, morning, Lior will lead the roundtable: "Understanding Investor Perspectives on Exosome Therapeutics to Navigate Risk Reward Clinical Validation & Platform Scalability in a Growing Field."

Dr. Kizhner will also participate as a member of the conference's expert speaker faculty, bringing Nurexone's scientific, development and manufacturing perspective to discussions around translating exosome therapeutics toward clinical and commercial development.

LSX Congress USA -- Sept. 22 to Sept. 24, 2026

Dr. Shaltiel will be part of the panel "Proof to Payoff: Building and Financing Translation-Ready Biotechs" on Sept. 23 in a session that will address fundable development milestones, financing structures and organizational models for biotechnology companies moving promising science toward commercialization.

BioProcess International -- Sept. 22 to Sept. 25, 2026

On Sept. 25, Dr. Shaltiel will present: "Unlocking the Regenerative Potential of Exosomes: From Bioprocess Development to Advanced Drug Delivery Platform." The presentation will focus on the intersection of exosome bioprocess development, scalable manufacturing and the potential use of exosomes as advanced therapeutic delivery vehicles.

World Medical Innovation Forum -- Sept. 22 to Sept. 23, 2026

Dr. Shaltiel will also attend the invitation-only World Medical Innovation Forum, presented by Mass General Brigham and Bank of America. The Forum brings together senior health care executives, investors, clinicians, scientists and industry leaders to examine emerging technologies, manufacturing, investment, regulatory challenges and other issues shaping the future of health care.

Nurexone's participation across the four events comes as the company continues to advance its lead therapeutic candidate, ExoPTEN, toward clinical development for acute spinal cord injury while pursuing initiatives intended to support future U.S. manufacturing and commercial activities.

Investor awareness engagement with RedChip

The company has entered into a non-exclusive investor relations agreement dated Sept. 8, 2026, with RedChip Companies Inc., an arm's-length service provider based in Maitland, Fla. RedChip will write, produce and distribute a 30-second television advertisement for the company as part of a two-week national television campaign expected to include 40 airings on either Fox Business National TV or CNBC National TV. David Gentry, RedChip's chief executive officer, is the principal responsible for the engagement.

Subject to acceptance by TSX Venture Exchange, the agreement has an initial 90-day term commencing on the later of Sept. 8, 2026, and the date of TSX-V acceptance. The company will pay RedChip a one-time cash fee of $65,000 (U.S.). RedChip will not receive any securities of the company as compensation. RedChip has represented to the company that neither RedChip nor, to its knowledge after reasonable inquiry, its directors, officers, principals, control persons, key employees, contractors, subcontractors or other persons performing services under the agreement currently own or control any securities of the company or have any right or present intention to acquire such securities. RedChip will not commence providing services until TSX-V acceptance has been obtained.

About RedChip Companies Inc.

RedChip is an investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992, RedChip provides investor relations and communications services, including investor outreach, retail and institutional roadshows, digital media, investor webinars, research distribution, and strategic consulting.

About Nurexone Biologic Inc.

Nurexone is a TSX-V-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, facilitate the company's road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top to anchor its North American activity and growth strategy.

We seek Safe Harbor.